Infusion treatments for multiple sclerosis can sound intimidating. There is an IV line, a collection of monitors, several medications with namesan especially competitive spelling bee, and usually a very serious-looking recliner. Yet for many people with MS, infusion therapy offers powerful disease control without the need to remember a daily pill or frequent injection.
These treatments are not interchangeable. Some target B cells, one limits immune-cell movement into the central nervous system, and another broadly resets parts of the immune system. Their schedules, benefits, monitoring requirements, and potential side effects differ substantially. Understanding those differences can make treatment conversationsand infusion day itselffar less mysterious.
What Are MS Infusion Treatments?
An infusion delivers medication directly into a vein through an intravenous, or IV, line. Depending on the drug, an infusion may take about an hour or occupy much of the day. Treatment may occur every four weeks, every six months, or in concentrated courses separated by a year.
Most long-term MS infusions are disease-modifying therapies, commonly called DMTs. They are intended to reduce inflammatory disease activity, including relapses and new or enlarging MRI lesions. Some also lower the risk of disability progression. They do not cure MS, instantly reverse established nerve damage, or replace treatments for symptoms such as pain, fatigue, stiffness, or bladder problems.
Disease-modifying infusions versus relapse treatment
Not every IV treatment given to someone with MS is a long-term DMT. High-dose intravenous corticosteroids, such as methylprednisolone, may be used for a significant relapse. Steroids can shorten the duration of a relapse, but they do not alter the long-term course of MS.
For a severe relapse that does not respond adequately to steroids, clinicians may consider plasma exchange. This procedure removes plasma containing harmful immune substances and replaces it with another fluid. It is not a routine maintenance infusion and is generally reserved for selected, serious attacks.
Common Infusion Treatments for Multiple Sclerosis
Ocrelizumab (Ocrevus)
Ocrelizumab is an anti-CD20 monoclonal antibody. It reduces certain B cells involved in the immune attack that damages myelin and nerve fibers. It is FDA-approved for relapsing forms of MS and primary progressive MS in adults.
In May 2026, the FDA also approved intravenous ocrelizumab for relapsing-remitting MS in pediatric patients age 10 and older who meet the minimum weight requirement. This was an important expansion because pediatric-onset MS has historically had fewer high-efficacy treatment options. p>For most adults, the first treatment is divided into two infusions given two weeks apart. Later doses are generally administered once every six months. Selected patients who tolerated earlier doses may qualify for a shorter infusion protocol.
Common concerns include infusion reactions and respiratory infections. More serious considerations include hepatitis B reactivation, declining immunoglobulin levels, serious infections, liver injury, immune-mediated colitis, and a possible malignancy risk. Rare cases of progressive multifocal leukoencephalopathy, or PML, have also been reported.
Ublituximab-xiiy (Briumvi)
Ublituximab is another anti-CD20 therapy, but it is approved only for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
The initial dose is followed by a second infusion two weeks later. Maintenance treatment is then generally given about every six months. Later infusions can be substantially shorter than the first when treatment is tolerated well.
Infusion reactions are particularly common with the first dose. Fever, chills, headache, nausea, flu-like symptoms, throat irritation, flushing, and a rapid heartbeat may occur. Steroids and an antihistamine are typically given before treatment to reduce the likelihood or severity of these reactions. Other important risks include infections, hepatitis B reactivation, reduced immunoglobulins, liver injury, and possible fetal harm.
Natalizumab (Tysabri and Tyruko)
Natalizumab works differently from anti-CD20 drugs. It helps prevent inflammatory immune cells from crossing the blood-brain barrier and entering the brain and spinal cord. Tysabri is the original product, while Tyruko is an FDA-approved biosimilar.
Natalizumab is generally infused every four weeks and is used for relapsing forms of MS. It can be highly effective, but its most discussed risk is PML, a rare and potentially fatal brain infection caused by reactivation of the John Cunningham virus, usually called the JC virus.
PML risk is assessed using factors such as JC-virus antibody status, treatment duration, antibody index, and previous use of immunosuppressive drugs. Patients typically undergo repeated blood testing, neurological assessments, and MRI monitoring. Natalizumab treatment is provided through a restricted safety program in the United States. p>Other possible side effects include headache, fatigue, joint pain, nausea, urinary tract infections, respiratory infections, allergic reactions, and liver injury. Symptoms such as new weakness, vision changes, confusion, clumsiness, or personality changes require urgent medical evaluation rather than a “let’s see how I feel next week” approach.
Alemtuzumab (Lemtrada)
Alemtuzumab targets CD52, a protein found on several types of immune cells. It produces a substantial reduction in circulating immune cells, followed by gradual immune-system repopulation.
Treatment is delivered in courses rather than continuously. The first course usually consists of five consecutive infusion days. A second three-day course is given 12 months later, and selected patients may receive additional courses. Because of its safety profile, alemtuzumab is generally reserved for adults with relapsing MS who have not responded adequately to at least two other MS medicines.
Its boxed warnings include serious autoimmune disease, severe infusion reactions, stroke, arterial dissection, and malignancy. Potential delayed autoimmune complications include thyroid disease, low platelets, kidney inflammation, autoimmune liver disease, and blood-cell disorders. Monthly blood and urine monitoring is required until 48 months after the last dose, even when the person feels perfectly well and would much rather forget that laboratory buildings exist.
Mitoxantrone and off-label rituximab
Mitoxantrone, historically sold as Novantrone, is an infused immune-suppressing drug that may still appear on lists of MS treatments. Its use has become uncommon because it can cause permanent heart damage, infertility, and treatment-related leukemia. Lifetime exposure is limited, and careful cardiac testing is required.
Rituximab is another anti-CD20 infusion that is used off-label by some MS specialists. “Off-label” means the FDA has approved the drug for other conditions, but not specifically for MS. Its use depends on the clinician, medical circumstances, evidence review, insurance coverage, and availability. The Department of Veterans Affairs includes both mitoxantrone and rituximab among infusion options considered in MS care, while distinguishing rituximab’s off-label status. ection>
MS Infusion Treatment Comparison
| Treatment | Typical use | General schedule | Major safety concerns |
|---|---|---|---|
| Ocrelizumab | Adult relapsing MS and primary progressive MS; selected pediatric RRMS | Two starter doses, then approximately every six months | Infusion reactions, infections, hepatitis B reactivation, low immunoglobulins |
| Ublituximab | Relapsing forms of MS in adults | Starter doses two weeks apart, then approximately every six months | Infusion reactions, infections, hepatitis B reactivation, low immunoglobulins |
| Natalizumab | Relapsing forms of MS in adults | Usually every four weeks | PML, allergic reactions, infections, liver injury |
| Alemtuzumab | Relapsing MS after inadequate response to other therapies | Five-day course, then a three-day course one year later | Autoimmune disease, infusion reactions, stroke, infections, malignancy |
| Mitoxantrone | Rarely used for selected worsening disease | Individualized, with a strict lifetime limit | Heart damage, leukemia, infertility, infection |
Common Side Effects During or After an MS Infusion
An infusion reaction occurs when the body responds to the medication during treatment or within the hours afterward. It is not always a true allergy. The reaction may be caused by rapid immune-cell changes and the release of inflammatory signaling molecules.
Possible symptoms include:
- Headache, fatigue, dizziness, or nausea
- Fever, chills, flushing, or sweating
- Itching, rash, or hives
- Throat irritation, coughing, or wheezing
- Changes in blood pressure or heart rate
- Shortness of breath or chest discomfort
- Muscle aches or flu-like symptoms
The care team may slow or pause the infusion, provide additional medication, monitor vital signs, and restart at a lower rate after symptoms improve. A severe reaction may require permanent discontinuation of the drug.
Most infusion protocols use premedication. This commonly includes an IV or oral corticosteroid and an antihistamine; acetaminophen may also be offered. Unfortunately, the preventive drugs have personalities of their own. Antihistamines may cause sleepiness, while corticosteroids may cause temporary insomnia, restlessness, mood changes, a metallic taste, indigestion, or elevated blood sugar.
Serious Risks That Require Ongoing Monitoring
Infections
Infused DMTs alter immune activity, so infections may occur more easily or become more serious. Patients should tell the infusion center about fever, persistent cough, painful urination, shingles symptoms, an infected wound, or recent antibiotic treatment. An infusion may be postponed until an active infection has resolved.
Hepatitis B reactivation
Anti-CD20 therapies can reactivate a previous hepatitis B infection. Screening is therefore required before ocrelizumab or ublituximab begins. A person with evidence of previous exposure may need consultation with a liver or infectious-disease specialist and additional monitoring.
Low immunoglobulin levels
Immunoglobulins are antibodies that help the body fight infection. Repeated B-cell-depleting therapy can lower these levels. Clinicians may periodically measure immunoglobulins, especially when a patient develops recurrent or unusually severe infections.
PML
PML is most strongly associated with natalizumab, although cases have been reported with other immune-modifying therapies. Symptoms can resemble an MS relapse, which is exactly why new neurological changes should be reported promptly rather than self-diagnosed.
Autoimmune complications
Alemtuzumab can trigger autoimmune problems months or years after treatment. Continued laboratory monitoring is essential even after infusion courses are complete. Skipping follow-up because treatment “finished ages ago” can allow a silent complication to become a loud one.
What Happens Before an Infusion?
The exact checklist depends on the medication, but preparation may include:
- A review of infections, new symptoms, allergies, and recent medications
- Complete blood count and liver-function testing
- Hepatitis B screening
- Immunoglobulin measurement before anti-CD20 treatment
- Pregnancy and family-planning discussions when relevant
- JC-virus antibody testing before and during natalizumab therapy
- Vaccination review before immune suppression begins
- Baseline MRI imaging and, for some drugs, cardiac or thyroid testing
Vaccines should ideally be discussed before therapy begins. Live vaccines are generally avoided during treatment with strongly immune-suppressing medications and until immune recovery. Non-live vaccines may be less effective when given during B-cell depletion, so timing can matter. Current prescribing information recommends completing live vaccines at least four weeks and, when possible, non-live vaccines at least two weeks before beginning ocrelizumab. ection>
What to Expect on Infusion Day
After check-in, a nurse reviews symptoms and recent health changes, records vital signs, and places the IV. Premedications are given first. The MS medication then starts at a controlled rate, which may gradually increase if no reaction occurs.
Blood pressure, pulse, breathing, temperature, and symptoms are monitored throughout treatment. Depending on the medication and treatment number, observation may continue for an hour or longer after the infusion ends.
Useful items include water, a snack, a charger, headphones, comfortable layers, and something mildly entertaining. A thrilling eight-hour historical epic may be ambitious after an antihistamine. Transportation help may be wise for a first infusion, especially when premedication causes drowsiness.
How Doctors Choose an Infusion Treatment
The “best” infusion is not simply the one with the highest efficacy statistic. Treatment selection is based on a benefit-risk discussion that may include:
- The type and activity of MS
- Recent relapses and MRI changes
- Age, disability level, and other medical conditions
- Previous DMT response and side effects
- Infection history and vaccination status
- JC-virus antibody results
- Pregnancy plans and breastfeeding considerations
- Travel distance, infusion-center access, and insurance coverage
- Personal tolerance for risk and laboratory monitoring
For example, ocrelizumab may be considered for primary progressive MS because it is the only FDA-approved infused DMT for that adult MS form. Natalizumab may offer strong control of highly active relapsing disease but requires careful PML risk assessment. Alemtuzumab offers infrequent treatment courses, yet it carries unusually extensive long-term monitoring obligations.
Conclusion
Infusion treatments can provide highly effective control of multiple sclerosis, often with schedules that are easier to maintain than daily medication. Convenience, however, should never be confused with simplicity. Each therapy affects the immune system differently and comes with its own laboratory tests, infection precautions, infusion-reaction plan, and long-term safety considerations.
The most useful question is not merely, “Which infusion is strongest?” It is, “Which treatment offers the right balance of effectiveness, safety, monitoring, and practicality for this particular person?” That answer should come from shared decision-making with an MS specialist who understands both the medical chart and the life happening outside it.
Experiences People Commonly Report With MS Infusion Therapy
The following examples are composite scenarios based on commonly described infusion experiences. They are not individual medical testimonials, and reactions vary considerably from one patient to another.
The first-infusion nerves
Many people say the anticipation is worse than the actual appointment. The first visit can feel like entering an unfamiliar airport where every announcement involves your immune system. There are forms, vital signs, medications, tubing, and questions about symptoms that may have seemed unimportant the previous evening.
Once treatment starts, the routine often becomes more predictable. Nurses explain what sensations to report, check the IV, and adjust the rate when necessary. Mild throat itching, flushing, chills, or a headache may lead to a temporary pause and additional medication. Reporting symptoms early is important; the infusion suite is not the place to win an award for quietly enduring things.
The post-infusion slump
Some patients feel normal afterward and resume their usual schedule. Others describe a day or two of fatigue, headache, mild body aches, or a “washed out” feeling. The medication itself, hours spent sitting, poor sleep, an antihistamine, and steroid premedication can all contribute.
A person may be sleepy during the appointment because of diphenhydramine, then oddly energetic at midnight because of the steroid. This pharmaceutical tag team can make the body unsure whether it is preparing for hibernation or reorganizing the garage. Keeping the next day relatively flexible can help, particularly after a first dose.
Steroid side effects that steal the spotlight
For some people, the premedication is more noticeable than the MS drug. Common reports include a metallic taste, increased appetite, facial warmth, irritability, insomnia, or temporary blood-sugar elevation. Sugar-free candy or strongly flavored gum may help with an unpleasant taste. Patients with diabetes may need a specific glucose-monitoring plan.
Making the routine manageable
Experienced infusion patients often develop a small ritual. They wear clothing that gives nurses easy access to the arm, bring multiple entertainment options, pack a snack that does not crumble into the IV tubing, and download content before arriving in case the clinic’s Wi-Fi has emotionally resigned.
Hydration may make IV placement easier unless a clinician has advised fluid restriction. Eating beforehand can also help, especially when steroids or other premedications irritate the stomach. Patients who become drowsy often arrange a ride rather than discovering halfway home that their eyelids have filed for early retirement.
The emotional side of treatment
Infusion day can create mixed feelings. Receiving a high-efficacy treatment may bring reassurance, but it can also make MS feel unusually visible. Some people experience anxiety before every appointment, while others regard the clinic as a temporary workspace, reading room, or scheduled nap facility.
Over time, many patients say the most reassuring part is knowing what to expect: which laboratory tests are required, how the medication feels, what foods to bring, and how long recovery usually takes. A treatment diary can help track headaches, sleep disruption, fever, fatigue, or other symptoms after each visit. Patterns recorded over several infusions can support more productive conversations with the care team.
When an experience should not be considered routine
Difficulty breathing, facial or throat swelling, severe chest pain, fainting, stroke symptoms, high fever, unusual bruising, jaundice, or new neurological problems require immediate medical attention. New symptoms should not automatically be blamed on MS, normal infusion fatigue, or “just one of those days.”
The goal is not to become afraid of every sensation. It is to understand the difference between an expected temporary effect and a warning sign. A written action plan from the infusion centerincluding daytime and after-hours contact informationcan remove much of the guesswork.
